| URL | https://www.fiercepharma.com/manufacturing/emergen |
| Source | Fierce Pharma |
| Date Published | 06/18/2020 |
| Author Name | Kyle Blankenship |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Emergent BioSolutions |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2020 |
| Year reshoring implemented or to be implemented: | 2023 |
| Capital investment ($): | 75 |
| City reshored to: | Canton |
| State(s) reshored to: | MA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | viral vectors for vaccines |
| What domestic positive factors made reshoring more attractive? | Government Incentives, covid-19 |